Login to Your Account

Cytos Slashes Programs, Jobs To Keep Allergy Candidate Alive

By Catherine Shaffer

Thursday, August 18, 2011
Cytos Biotechnology Ltd. is taking drastic measures to keep the company afloat ahead of the looming maturity of its convertible bond in February 2012. Although its product, CYT003-QbG10, has shown positive results in three Phase II trials for allergic asthma and allergic rhinitis, the company has been unable to fund its earlier stage programs, and may face a financing gap of more than $21.5 million even after it slashes its staff and programs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription